Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe.
The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and Epstein-Barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella, and other viral pathogens. It also provides products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at risk of developing diabetes.
Additionally, the company provides laboratory-testing services for Sjogren's syndrome, hearing loss, celiac disease, lupus, rheumatoid arthritis, systemic sclerosis, and other laboratory-testing services for autoimmune disorders.
In addition, the company develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats. It also provides reagent products, such as ACE, bile acids, oxalate, and glucose-6-phosphate dehydrogenase for the diagnosis of liver and kidney diseases, as well as haemolytic anaemia.
It serves public health authorities, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
